{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:07:43Z","timestamp":1759018063833,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,27]]},"DOI":"10.7759\/cureus.93342","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:48:11Z","timestamp":1758984491000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-TNF-Related Medium-Vessel Vasculitis: A Report of a Rare Adverse Drug Reaction"],"prefix":"10.7759","author":[{"given":"Mehrnoush","family":"Hassas Yeganeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arooba","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Zefreh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Shostak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajina","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001512","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs NM","year":"2021","unstructured":"Roodenrijs NM, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, Welsing PM. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021, 7:10.1136\/rmdopen-2020-001512","journal-title":"RMD Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha D","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018, 320:1360-72. 10.1001\/jama.2018.13103","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0197-y","article-title":"Certolizumab pegol: a review in inflammatory autoimmune diseases","volume":"30","author":"Deeks ED","year":"2016","unstructured":"Deeks ED. Certolizumab pegol: a review in inflammatory autoimmune diseases. BioDrugs. 2016, 30:607-17. 10.1007\/s40259-016-0197-y","journal-title":"BioDrugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12693","article-title":"Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: report of a case and review of the literature","volume":"31","author":"Babuna Kobaner G","year":"2018","unstructured":"Babuna Kobaner G, Polat Ekinci A, Yilmaz Z, Copur S. Psoriasiform skin eruption in a patient receiving certolizumab-pegol for ankylosing spondylitis: report of a case and review of the literature. Dermatol Ther. 2018, 31:e12693. 10.1111\/dth.12693","journal-title":"Dermatol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06406-6","article-title":"Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature","volume":"42","author":"Ak T","year":"2023","unstructured":"Ak T, Durmus RB, Onel M. Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature. Clin Rheumatol. 2023, 42:339-57. 10.1007\/s10067-022-06406-6","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.67","article-title":"Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls","volume":"2","author":"Silva LC","year":"2010","unstructured":"Silva LC, Ortigosa LC, Benard G. Anti-TNF-\u03b1 agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010, 2:817-33. 10.2217\/imt.10.67","journal-title":"Immunotherapy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11467","article-title":"Side effects of methotrexate and tumor necrosis factor inhibitors: differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis","volume":"4","author":"Ogdie A","year":"2022","unstructured":"Ogdie A, Maksabedian Hernandez EJ, Shaw Y, Stolshek B, Michaud K. Side effects of methotrexate and tumor necrosis factor inhibitors: differences in tolerability among patients with psoriatic arthritis and rheumatoid arthritis. ACR Open Rheumatol. 2022, 4:935-41. 10.1002\/acr2.11467","journal-title":"ACR Open Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04242.x","article-title":"Adalimumab-induced medium-sized vessel vasculitis","volume":"37","author":"Bakkour W","year":"2012","unstructured":"Bakkour W, Coulson IH, Sahasrabudhe N. Adalimumab-induced medium-sized vessel vasculitis. Clin Exp Dermatol. 2012, 37:562-4. 10.1111\/j.1365-2230.2011.04242.x","journal-title":"Clin Exp Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"38","author":"Exarchou SA","year":"2009","unstructured":"Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009, 38:328-31. 10.1080\/03009740902922612","journal-title":"Scand J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen G","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011, 34:1318-27. 10.1111\/j.1365-2036.2011.04866.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.07.019","article-title":"Safety of long-term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials","volume":"14","author":"Loftus EV Jr","year":"2016","unstructured":"Loftus EV Jr, Colombel JF, Schreiber S, et al.. Safety of long-term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol. 2016, 14:1753-62. 10.1016\/j.cgh.2016.07.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert C","year":"2019","unstructured":"Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019, 99:115-60. 10.1152\/physrev.00045.2017","journal-title":"Physiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15360","article-title":"Dermatologic adverse events caused by biologic treatments - pathogenesis and management","volume":"22","author":"Trefzer LK","year":"2024","unstructured":"Trefzer LK, Pilz AC, Eyerich K. Dermatologic adverse events caused by biologic treatments - pathogenesis and management. J Dtsch Dermatol Ges. 2024, 22:1126-36. 10.1111\/ddg.15360","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14583","article-title":"Pathomechanism of adverse reactions to biological treatment of inflammatory skin conditions","volume":"54","author":"Li L","year":"2024","unstructured":"Li L, Naisbitt DJ, Sun Y, Zhang F. Pathomechanism of adverse reactions to biological treatment of inflammatory skin conditions. Clin Exp Allergy. 2024, 54:973-83. 10.1111\/cea.14583","journal-title":"Clin Exp Allergy"},{"key":"ref15","article-title":"The molecular basis of autoimmune diseases","volume":"31","author":"Lee B","year":"2024","unstructured":"Lee B. The molecular basis of autoimmune diseases. American Journal of Biological Sciences. 2024, 31:1-6.","journal-title":"American Journal of Biological Sciences"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/0973-3698.272156","article-title":"Drug-induced vasculitis","volume":"5","author":"Misra D","year":"2019","unstructured":"Misra D, Patro P, Sharma A. Drug-induced vasculitis. Indian J Rheumatol. 2019, 5:3-9. 10.4103\/0973-3698.272156","journal-title":"Indian J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini A","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review. Clin Rheumatol. 2018, 37:2579-84. 10.1007\/s10067-018-4177-0","journal-title":"Clin Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji UN","year":"2019","unstructured":"Shivaji UN, Sharratt CL, Thomas T, et al.. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019, 49:664-80. 10.1111\/apt.15097","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093165","article-title":"Leukocytoclastic vasculitis secondary to anti-tumor necrosis factor therapy in inflammatory bowel diseases: a multicenter retrospective cohort study","volume":"12","author":"Parra RS","year":"2023","unstructured":"Parra RS, Chebli JM, Chebli LA, et al.. Leukocytoclastic vasculitis secondary to anti-tumor necrosis factor therapy in inflammatory bowel diseases: a multicenter retrospective cohort study. J Clin Med. 2023, 12:3165. 10.3390\/jcm12093165","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18136711","article-title":"Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report","volume":"18","author":"Giorgio V","year":"2021","unstructured":"Giorgio V, Blasi E, Rigante D, et al.. Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18136711","journal-title":"Int J Environ Res Public Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/403192-anti-tnf-related-medium-vessel-vasculitis-a-report-of-a-rare-adverse-drug-reaction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:48:12Z","timestamp":1758984492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/403192-anti-tnf-related-medium-vessel-vasculitis-a-report-of-a-rare-adverse-drug-reaction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.93342","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,27]]}}}